Contribution of mitogen-activated protein kinase to stimulation of phospholipase D by the chemotactic peptide fMet-Leu-Phe in human neutrophils.

Phospholipase D (PLD) plays an important role in signaling through phosphatidylcholine (PC) and in the production of superoxide (respiratory burst) by polymorphonuclear leukocytes (PMN) stimulated by the chemoattractant fMet-Leu-Phe (fMLP). However, the regulation of PLD activity by protein kinases is not fully understood. In the present study, we have used a mitogen-activated protein (MAP) kinase inhibitor (PD 98059) to investigate a possible connection between extracellular signal-regulated kinase (ERK) and PLD activity and respiratory burst. Using a range of concentrations (3-20 microM) which inhibit ERK activity, PD 98059 inhibited PLD activity induced by fMLP in cytochalasin B-primed PMN, as assessed by production-tritiated phosphatidylethanol (PEt), phosphatidic acid (PA), and hydrolysis of PC. However, the inhibition was partial (approximately 50%), while inhibition of PC hydrolysis was almost complete, suggesting a concomitant inhibition of PLA2 activity. In addition, PD 98059 reduced fMLP-induced respiratory burst by 50%, an effect which was correlated with PLD inhibition of PLD (r = 0.981, P < 0.01), and neither did PD 98059 inhibit the PLD activity and respiratory burst induced by PKC upon its direct activation by phorbol myristate acetate. These data provide the first evidence for implication of the ERK cascade in the stimulation of PLD through Gi signaling. They further indicate that PLD stimulation by fMLP receptors occurs through two pathways, dependent and independent on MAP kinase, the former pathway being linked to superoxide production.

Contrasting effects of calyculin A and okadaic acid on the respiratory burst of human neutrophils.

The involvement of serine/threonine protein-phosphatases in the production of superoxide (respiratory burst) by human neutrophils was investigated using calyculin A, a potent inhibitor of both protein phosphatases type 1 and 2A, and okadaic acid, which preferentially inhibits protein phosphatase type 2A. Treatment of neutrophils with calyculin A (25-75 nM) or okadaic acid (1-4 microM) had no stimulatory effect but potently enhanced total superoxide production induced by an optimal fMLP (N-formyl-methionyl-leucyl-phenylalanine) concentration (0.1 microM). The maximum increase plateaued with 50-75 nM calyculin A and 2-4 microM okadaic acid, reaching approximately 120 and 200% of control values, respectively. Unlike calyculin A, okadaic acid also primed the initial rate of superoxide production, suggesting that protein phosphatases may down-regulate both initiation and termination of respiratory burst. Optimal stimulation of the respiratory burst by PMA (160 nM) was inhibited by calyculin A and okadaic acid, with an IC50 of 60 nM and 2 microM, respectively, although both drugs caused protein hyperphosphorylation. The inhibition was partially prevented by a nonstimulatory concentration of A23187, indicating a role of calcium in the inhibitory effects of the drugs. Unlike the optimal respiratory burst, suboptimal respiratory burst induced by PMA (1-7 nM) was enhanced by calyculin A and okadaic acid. Unprimed and primed respiratory bursts were depressed by a selective antagonist of protein kinase C (GF 109203X), indicating positive regulation of these responses by protein kinase C. Thus, the use of calyculin A and okadaic acid distinguishes two regulatory processes of superoxide production.(ABSTRACT TRUNCATED AT 250 WORDS)

Okadaic acid, an inhibitor of type 1 and type 2A phosphatases, modulates the activation of phospholipase D in formyl peptide- and mastoparan-stimulated human neutrophils.

The activation of phospholipase D (PLD) induced by formyl peptides (fMLP), as evaluated by production of tritiated phosphatidylethanol (PEt) and phosphatidic acid (PA) in polymorphonuclear leukocytes (PMN), was markedly enhanced (50-125%) by low okadaic acid concentrations (0.25-0.5 microM) but inhibited by higher concentrations (2-3 microM), although the drug caused protein hyperphosphorylation. Both effects of okadaic acid were amplified when PLD activation was primed with cytochalasin B. Stimulation of PMN with mastoparan, a wasp venom toxin that activates Pertussis toxin(PTX)-sensitive G proteins, resulted in a weak calcium-dependent production of PEt which was respectively enhanced and inhibited by okadaic acid (1-2 microM) in unprimed and cytochalasin-primed PMN. The results show that low okadaic acid concentrations primed fMLP-mediated activation of PLD, in keeping with a down-regulatory role of protein phosphatases. The contrasting effects of okadaic acid in mastoparan-stimulated PMN further suggest that protein phosphatases may regulate the generation of second messengers through alteration of major signaling events at/or downstream of PTX-sensitive G proteins (Gi).

Staurosporine stimulates phospholipase D activation in human polymorphonuclear leukocytes.

Treatment of 1-O-[3H]alkyl-2-acyl-phosphatidylcholine-prelabeled human polymorphonuclear leukocytes (PMNs) with staurosporine (50 nM to 1 microM) induced a time- and concentration-dependent generation of tritiated phosphatidic acid (PA), reaching approximately 225% of the control value at 15-20 min. In the presence of ethanol, staurosporine induced a production of phosphatidylethanol (PEt) reaching, 250% of control values, and partial inhibition of PA production, consistent with PLD activation. The amount of ether-linked acylglycerol (EAG) was weakly enhanced (29%) after 5 min of PMN treatment; longer treatment resulted in no significant EAG production, suggesting a possible late inhibition of PA hydrolase activity. Staurosporine concentrations that induced an elevation in PA completely depressed protein kinase C (PKC) activity in both soluble and particulate cell fractions, suggesting that PLD activation may occur independently from PKC activation. PLD may thus represent a potential cellular target for staurosporine action.